A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.
On Jan. 5, the Centers for Disease Control and Prevention released a scaled-back childhood vaccine schedule that slashed the number of diseases that the institution recommends all children get immunized against—from 17 to 11.
